ABBV

NYSE

AbbVie Inc.

Health Care, Biotechnology

$246.04

close 7 Aug 2026

+23.86%

52-week change

$434.78B

market cap

$190.75

$267.47

52-week range

Valuation

Market cap$434.78B

P/E (TTM / 5y avg)69.50x59.25x

Forward P/E (FY2026 / FY2027)17.56x15.06x

PEG (TTM / fwd)—1.06

P/S (TTM)6.75x

P/B-73.26x

EV/EBITDA (TTM)28.28x

FCF yield (TTM)4.19%

Cash flow & dividend

FCF (TTM)$18.21B

FCF per share (TTM)$10.30

FCF margin (TTM)28.28%

Dividend yield (indicated / 5y avg)2.81%3.64%

Annualized dividend$6.92

Payout ratio (EPS / FCF)189.83%65.78%

Growth & quality

Revenue YoY, latest Q+10.16%

Diluted EPS YoY, latest Q+290.38%

Operating margin (TTM)26.20%

Net margin (TTM)9.80%

ROE (latest FY)—

Net debt / EBITDA (TTM)3.64

Interest coverage (TTM)5.79

Price

+111.23%+16.19%/yrover 5y

Weekly closes · split-adjusted

close 7 Aug 2026

Fundamentals

Fiscal years, last 10, CAGR chips on growth series, plus a dimmed trailing-twelve-month bar

Revenue

5Y CAGR +5.95%10Y CAGR +10.34%

Diluted EPS

5Y CAGR -2.80%10Y CAGR -2.78%

FCF per share

5Y CAGR +0.11%10Y CAGR +8.85%

Operating cash flow

5Y CAGR +1.59%10Y CAGR +9.71%

Free cash flow

5Y CAGR +1.19%10Y CAGR +9.79%

Dividends per share

5Y CAGR +7.44%10Y CAGR +12.50%

Payout ratio

FCF payout ratio

Operating margin

FCF margin

Return on equity

Return on capital employed

Shares outstanding

5Y CAGR +1.08%10Y CAGR +0.86%

Net debt / EBITDA

Interest coverage

Earnings

Street estimates, not SEC filings

Next / Q3 FY26

Date29 Oct 2026

EPS estimate$3.93

Revenue estimate$17.67B

Last reported

Date—

EPS——

Revenue——